Pleiotropic behavior of 5-HT2A and 5-HT2C receptor agonists

被引:58
作者
Berg, KA
Maayani, S
Goldfarb, J
Clarke, WP
机构
[1] Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78284 USA
[2] Mt Sinai Med Ctr, Dept Anesthesiol, New York, NY 10029 USA
[3] Mt Sinai Med Ctr, Dept Pharmacol, New York, NY 10029 USA
来源
ADVANCES IN SEROTONIN RECEPTOR RESEARCH: MOLECULAR BIOLOGY, SIGNAL TRANSDUCTION, AND THERAPEUTICS | 1998年 / 861卷
关键词
D O I
10.1111/j.1749-6632.1998.tb10180.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
There is now considerable evidence that a single receptor subtype can couple to multiple effector pathways within a cell. Recently, Kenakin proposed a new concept, termed "agonist-directed trafficking of receptor stimulus", that suggests that agonists may be able to selectively activate a subset of multiple signaling pathways coupled to a single receptor subtype. 5-HT2A and 5-HT2C receptors couple to phospholipase C-(PLC) mediated inositol phosphate (IP) accumulation and PLA(2)-mediated arachidonic acid (AA) release. Relative efficacies of agonists (referenced to 5-HT) differed depending upon whether LP accumulation or AA release aas measured. For the 5-HT2C receptor system, some agonists (e.g. TFMPP) preferentially activated the PLC-IP pathway, whereas others (e.g. LSD) favored PLA(2)-AA. As expected, EC50's of agonists did not differ between pathways, For the 5-HT2A receptor system, all agonists tested had greater relative efficacy for PLA(2)-AA than for PLC-LP. In contrast, relative efficacies were not different for 5-HT2A agonists when sequential effects in a pathway were measured (IP accumulation vs. calcium mobilization). These data strongly support the agonist-directed trafficking hypothesis.
引用
收藏
页码:104 / 110
页数:7
相关论文
共 13 条
  • [1] BERG KA, 1994, MOL PHARMACOL, V46, P477
  • [2] Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: Evidence for agonist-directed trafficking of receptor stimulus
    Berg, KA
    Maayani, S
    Goldfarb, J
    Scaramellini, C
    Leff, P
    Clarke, WP
    [J]. MOLECULAR PHARMACOLOGY, 1998, 54 (01) : 94 - 104
  • [3] Berg KA, 1996, MOL PHARMACOL, V50, P1017
  • [4] CLARK AJ, 1937, HEFFNERS HDB DEXP PH, V4
  • [5] The elusive nature of intrinsic efficacy
    Clarke, WP
    Bond, RA
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 1998, 19 (07) : 270 - 276
  • [6] COSTA T, 1992, MOL PHARMACOL, V41, P549
  • [7] Furchgott R., 1966, ADV DRUG RES, V3, P21
  • [8] Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429
  • [9] AGONIST-RECEPTOR EFFICACY .2. AGONIST TRAFFICKING OF RECEPTOR SIGNALS
    KENAKIN, T
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 1995, 16 (07) : 232 - 238
  • [10] Kenakin T, 1996, PHARMACOL REV, V48, P413